Top

Published in:

01-07-2016 | Original Article

miR-15a and miR-24-1 as putative prognostic microRNA signatures for pediatric pilocytic astrocytomas and ependymomas

Authors: M. Braoudaki, G. I. Lambrou, K. Giannikou, S. A. Papadodima, A. Lykoudi, K. Stefanaki, G. Sfakianos, A. Kolialexi, F. Tzortzatou-Stathopoulou, M. Tzetis, S. Kitsiou-Tzeli, E. Kanavakis

Published in: Tumor Biology | Issue 7/2016

Abstract

In the current setting, we attempted to verify and validate miRNA candidates relevant to pediatric primary brain tumor progression and outcome, in order to provide data regarding the identification of novel prognostic biomarkers. Overall, 26 resected brain tumors were studied from children diagnosed with pilocytic astrocytomas (PAs) (n = 19) and ependymomas (EPs) (n = 7). As controls, deceased children who underwent autopsy and were not present with any brain malignancy were used. The experimental approach included microarrays covering 1211 miRNAs. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to validate the expression profiles of miR-15a and miR-24-1. The multiparameter analyses were performed with MATLAB. Matching differentially expressed miRNAs were detected in both PAs and EPs, following distinct comparisons with the control cohort; however, in several cases, they exhibited tissue-specific expression profiles. On correlations between miRNA expression and EP progression or outcome, miR-15a and miR-24-1 were found upregulated in EP relapsed and EP deceased cases when compared to EP clinical remission cases and EP survivors, respectively. Taken together, following several distinct associations between miRNA expression and diverse clinical parameters, the current study repeatedly highlighted miR-15a and miR-24-1 as candidate oncogenic molecules associated with inferior prognosis in children diagnosed with ependymoma.

Available only for authorised users

http://www.bioinformatics.lu/

Ha M, Kim VN. Regulation of microRNA biogenesis. Nature Rev Mol Cell Biol. 2014;15:509–24.CrossRef

Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Current genomics. 2010;11:537–61.CrossRefPubMedPubMedCentral

Braoudaki M, Lambrou GI. MicroRNAs in pediatric central nervous system embryonal neoplasms: the known unknown. J Hematol Oncol. 2015;8:6.CrossRefPubMedPubMedCentral

Braoudaki M, Lambrou GI, Giannikou K, Milionis V, Stefanaki K, Birks DK, et al. MicroRNA expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms. J Hematol Oncol. 2014;7:96.CrossRefPubMedPubMedCentral

Arunachalam G, Upadhyay R, Ding H, Triggle CR. MicroRNA signature and cardiovascular dysfunction. J Cardiovascular Pharmacol. 2015;65:419–29.CrossRef

Mohammad AA, Rahbar A, Lui WO, Davoudi B, Catrina A, Stragliotto G, et al. Detection of circulating hcmv-miR-UL112-3p in patients with glioblastoma, rheumatoid arthritis, diabetes mellitus and healthy controls. PLoS One. 2014;9:e113740.CrossRefPubMedPubMedCentral

Lycoudi A, Mavreli D, Mavrou A, Papantoniou N, Kolialexi A. MiRNAs in pregnancy-related complications. Expert Rev Mol Diagn. 2015;15:999–1010.CrossRefPubMed

Birks DK, Barton VN, Donson AM, Handler MH, Vibhakar R, Foreman NK. Survey of microRNA expression in pediatric brain tumors. Pediatr Blood Cancer. 2011;56:211–6.CrossRefPubMed

Braoudaki M, Lambrou GI, Papadodima SA, Stefanaki K, Prodromou N, Kanavakis E. MicroRNA expression profiles in pediatric dysembryoplastic neuroepithelial tumors. Medical Oncol (Northwood, London, England). 2016;33:5.CrossRef

10.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.CrossRefPubMedPubMedCentral

11.

Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 2005;33:W741–8.CrossRefPubMedPubMedCentral

12.

Agarwal V, Bell GW, Nam JW, Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. eLife 2015;4

13.

Paraskevopoulou MD, Georgakilas G, Kostoulas N, Reczko M, Maragkakis M, Dalamagas TM, et al. DIANA-LncBase: experimentally verified and computationally predicted microRNA targets on long non-coding RNAs. Nucleic Acids Res. 2013;41:D239–45.CrossRefPubMed

14.

Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M, et al. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 2013;41:W169–73.CrossRefPubMedPubMedCentral

15.

Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, et al. DIANA miRPath v. 2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 2012;40:W498–504.CrossRefPubMedPubMedCentral

16.

Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013;3:1302–15.CrossRefPubMed

17.

Song G, Gu L, Li J, Tang Z, Liu H, Chen B, et al. Serum microRNA expression profiling predict response to r-chop treatment in diffuse large B cell lymphoma patients. Annals Hematol. 2014;93:1735–43.CrossRef

18.

Huang E, Liu R, Chu Y. MiRNA-15a/16: as tumor suppressors and more. Future Oncol(London, England). 2015;11:2351–63.CrossRef

19.

Kramer K, Wu J, Crowe DL: Tumor suppressor control of the cancer stem cell niche. Oncogene 2015

20.

Lan F, Yue X, Ren G, Li H, Ping L, Wang Y, et al. miR-15a/16 enhances radiation sensitivity of non-small cell lung cancer cells by targeting the TLR1/NF-kappaB signaling pathway. Int J Radiat Oncol, Biol, physics. 2015;91:73–81.CrossRef

21.

Lopez-Bertoni H, Lal B, Li A, Caplan M, Guerrero-Cazares H, Eberhart CG, et al. DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2. Oncogene. 2015;34:3994–4004.CrossRefPubMed

22.

Mishra PJ, Song B, Mishra PJ, Wang Y, Humeniuk R, Banerjee D, et al. MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS One. 2009;4:e8445.CrossRefPubMedPubMedCentral

23.

Tian X, Zhang J, Yan L, Dong JM, Guo Q. MiRNA-15a inhibits proliferation, migration and invasion by targeting TNFAIP1 in human osteosarcoma cells. Int J Clin Exp Pathol. 2015;8:6442–9.PubMedPubMedCentral

24.

Tafsiri E, Darbouy M, Shadmehr MB, Zagryazhskaya A, Alizadeh J, Karimipoor M. Expression of miRNAs in non-small-cell lung carcinomas and their association with clinicopathological features. Tumour Biol. 2015;36:1603–12.CrossRefPubMed

25.

Yang T, Thakur A, Chen T, Yang L, Lei G, Liang Y, et al. MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer. Tumour Biol. 2015;36:4357–65.CrossRefPubMed

26.

Luo Q, Li X, Li J, Kong X, Zhang J, Chen L, et al. Mir-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol. 2013;43:1212–8.PubMed

27.

Kang W, Tong JH, Lung RW, Dong Y, Zhao J, Liang Q, et al. Targeting of YAP1 by MicroRNA-15a and MicroRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma. Mol Cancer. 2015;14:52.CrossRefPubMedPubMedCentral

28.

Fallah P, Amirizadeh N, Poopak B, Toogeh G, Arefian E, Kohram F, et al. Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Int J Lab Hematol. 2015;37:560–8.CrossRefPubMed

29.

Xiao G, Tang H, Wei W, Li J, Ji L, Ge J. Aberrant expression of microRNA-15a and microRNA-16 synergistically associates with tumor progression and prognosis in patients with colorectal cancer. Gastroenterology Res Pract. 2014;2014:364549.

30.

de Groen FL, Timmer LM, Menezes RX, Diosdado B, Hooijberg E, Meijer GA, et al. Oncogenic role of miR-15a-3p in 13q amplicon-driven colorectal adenoma-to-carcinoma progression. PLoS One. 2015;10:e0132495.CrossRefPubMedPubMedCentral

31.

Wu XJ, Pu XM, Zhao ZF, Zhao YN, Kang XJ, Wu WD, et al. The expression profiles of microRNAs in Kaposi’s sarcoma. Tumour Biol. 2015;36:437–46.CrossRefPubMed

32.

Costa FF, Bischof JM, Vanin EF, Lulla RR, Wang M, Sredni ST, et al. Identification of microRNAs as potential prognostic markers in ependymoma. PLoS One. 2011;6:e25114.CrossRefPubMedPubMedCentral

33.

Sand M, Skrygan M, Sand D, Georgas D, Gambichler T, Hahn SA, et al. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2013;351:85–98.CrossRefPubMed

34.

Inoguchi S, Seki N, Chiyomaru T, Ishihara T, Matsushita R, Mataki H, et al. Tumour-suppressive microRNA-24-1 inhibits cancer cell proliferation through targeting FOXM1 in bladder cancer. FEBS Lett. 2014;588:3170–9.CrossRefPubMed

35.

Luzi E, Marini F, Giusti F, Galli G, Cavalli L, Brandi ML. The negative feedback-loop between the oncomir Mir-24-1 and menin modulates the Men1 tumorigenesis by mimicking the “Knudson’s Second Hit”. PLoS One. 2012;7:e39767.CrossRefPubMedPubMedCentral

36.

Luzi E, Marini F, Tognarini I, Galli G, Falchetti A, Brandi ML. The regulatory network menin-microRNA 26a as a possible target for RNA-based therapy of bone diseases. Nucleic Acid Therapeutics. 2012;22:103–8.PubMed

37.

Nymark P, Guled M, Borze I, Faisal A, Lahti L, Salmenkivi K, et al. Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos- and histology-related changes in lung cancer. Genes Chromosom Cancer. 2011;50:585–97.CrossRefPubMed

38.

Zhao Z, Qin L, Li S: miR-411 contributes the cell proliferation of lung cancer by targeting FOXo1. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 2015

39.

Xia K, Zhang Y, Cao S, Wu Y, Guo W, Yuan W, et al. miR-411 regulated ITCH expression and promoted cell proliferation in human hepatocellular carcinoma cells. Biomed Pharmacother. 2015;70:158–63.CrossRefPubMed

40.

Nadal E, Zhong J, Lin J, Reddy RM, Ramnath N, Orringer MB, et al. A microRNA cluster at 14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res. 2014;20:3107–17.CrossRefPubMed

41.

Skalsky RL, Cullen BR. Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS One. 2011;6:e24248.CrossRefPubMedPubMedCentral

42.

Marti E, Pantano L, Banez-Coronel M, Llorens F, Minones-Moyano E, Porta S, et al. A myriad of miRNA variants in control and Huntington’s disease brain regions detected by massively parallel sequencing. Nucleic Acids Res. 2010;38:7219–35.CrossRefPubMedPubMedCentral

43.

Kawahara Y, Megraw M, Kreider E, Iizasa H, Valente L, Hatzigeorgiou AG, et al. Frequency and fate of microRNA editing in human brain. Nucleic Acids Res. 2008;36:5270–80.CrossRefPubMedPubMedCentral

Title: miR-15a and miR-24-1 as putative prognostic microRNA signatures for pediatric pilocytic astrocytomas and ependymomas
Authors: M. Braoudaki
G. I. Lambrou
K. Giannikou
S. A. Papadodima
A. Lykoudi
K. Stefanaki
G. Sfakianos
A. Kolialexi
F. Tzortzatou-Stathopoulou
M. Tzetis
S. Kitsiou-Tzeli
E. Kanavakis
Publication date: 01-07-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-4903-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2016

miR-488 acts as a tumor suppressor gene in gastric cancer

Cancer stem cell markers in pediatric sarcomas: Sox2 is associated with tumorigenicity in immunodeficient mice

Identification of novel NRAGE involved in the radioresistance of esophageal cancer cells

DACH1 inhibits the proliferation and invasion of lung adenocarcinoma through the downregulation of peroxiredoxin 3

Increased expression of SOX4 is associated with colorectal cancer progression

SUSD2 is frequently downregulated and functions as a tumor suppressor in RCC and lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer